Protherics signs ReGel™ licensing agreement with Myungmoon Pharm

Protherics PLCProtherics PLC, the international biopharmaceutical company focused on critical care and cancer, today announces that it has signed a licensing agreement with Myungmoon Pharm. Co. Ltd., a Korean pharmaceutical company, granting it the rights to develop anti-inflammatory products using Protherics' local, sustained release drug delivery system ReGel™.

Protherics will receive a small upfront payment on signing the agreement and royalties on any net sales in the Republic of Korea. Under the agreement, Protherics also has an option on agreed terms to the global rights outside of the Republic of Korea to any products developed under the agreement.

Mr G.H. Lee, President of Myungmoon Pharm. Co. Ltd. commented: "We are excited to have signed this agreement to use ReGel in the development of locally administered, sustained release anti-inflammatory products for arthritis and other potential indications."

Andrew Heath, Chief Executive of Protherics commented: "Protherics' ReGel is a unique drug delivery system, gained through our acquisition of MacroMed Inc, which has broad application beyond its use in OncoGel, our proprietary formulation of paclitaxel in phase II development for cancer. There is encouraging interest from a number of major companies to develop products utilising ReGel for a range of indications."

About ReGel™
ReGel™ is a novel thermosetting biodegradable gel that solidifies when injected into the body. It is designed for local administration where it is able to provide high concentrations of a drug for a sustained period. For more information about ReGel™'s use with OncoGel™ please visit http://www.protherics.com/Products/oncogel.aspx

About Myungmoon Pharm. Co. Ltd.
Myungmoon Pharma is a specialised and characterised pharmaceutical company based in the Republic of Korea, with a range of products including anesthetic agents, antibiotics, muscle relaxants, endocrine and cardiovascular products. In 2006 they turned over $51 million with a profit of over $5 million. More information can be found at http://www.mmpharm.co.kr/english/

About Protherics
Protherics (LSE: PTI, NASDAQ: PTIL) is a leading biopharmaceutical company focused on the development, manufacture and marketing of specialised products for critical care and cancer.

Protherics has developed and manufactures two critical care products currently sold in the US: CroFab™, a pit viper antivenom and DigiFab™, a digoxin antidote. The Company's strategy is to use the revenues generated from its marketed and out-licensed products to help fund the advancement of its broad, late stage pipeline.

Protherics has two major development opportunities in its critical care portfolio. CytoFab™ is being developed by AstraZeneca, for the treatment of severe sepsis, following a major £195 million (more than $340 million) licensing deal in December 2005. An additional, expanded phase II programme is planned to start in the second half of 2007. In addition, Protherics is currently undertaking a phase IIb study with Digoxin Immune Fab for the treatment of pre-eclampsia. This study is expected to report in the first half of 2008.

Protherics has a pipeline of four novel cancer products in clinical development, and intends to undertake the sales and marketing of these products in the US or the EU. Protherics is preparing to resubmit a BLA for Voraxaze™, an adjunct to high dose methotrexate therapy, under a rolling submission in the US starting in early 2008.

Protherics has a strong cash position, with unaudited cash balances at 30 June 2007 of £45m. With headquarters in London, the Company has approximately 270 employees across its operations in the UK, US and Australia.

For further information visit: www.protherics.com

Most Popular Now

Pfizer receives positive FDA Advisory Committee vo…

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that avail...

Engineered bacteria find tumors, then alert the au…

Combining discoveries in cancer immunology with sophisticated genetic engineering, Columbia University researchers have created a sort of "bacterial suicide squad" that ...

First nasal monoclonal antibody treatment for COVI…

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the ...

US FDA Advisory Committee votes to support effecti…

GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the avail...

"Semantic similarity" leads to novel dru…

The words that researchers use to describe their results can be harnessed to discover potential new treatments for Parkinson's disease, according to a new study published...

Tumour cells' response to chemotherapy is driven b…

Cancer cells have an innate randomness in their ability to respond to chemotherapy, which is another tool in their arsenal of resisting treatment, new research led by the...

Pfizer's ZAVZPRET™ (zavegepant) migraine nasal spr…

Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptid...

Pfizer invests $43 billion to battle cancer

Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a...

Gene and cell therapies to combat pancreatic cance…

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene an...

Scientists reveal a potential new approach to trea…

Scientists at the National Institutes of Health and Massachusetts General Hospital in Boston have uncovered a potential new approach against liver cancer that could lead ...

Normalizing tumor blood vessels may improve immuno…

A type of immune therapy called chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of multiple types of blood cancers but has shown limited e...

Digital twin opens way to effective treatment of i…

Inflammatory diseases like rheumatoid arthritis have complex disease mechanisms that can differ from patient to patient with the same diagnosis. This means that currently...